Blohm Ariane S, Mäder Patrick, Quack Thomas, Lu Zhigang, Hahnel Steffen, Schlitzer Martin, Grevelding Christoph G
BFS, Institut for Parasitology, Justus-Liebig-University Gießen, Gießen, 35392, Germany.
Institute for Pharmaceutic Chemistry, Philipps-University Marburg, Marburg, 35032, Germany.
Parasitol Res. 2016 Oct;115(10):3831-42. doi: 10.1007/s00436-016-5146-7. Epub 2016 May 26.
Schistosomes and other parasitic platyhelminths cause infectious diseases of worldwide significance for humans and animals. Despite their medical and economic importance, vaccines are not available and the number of drugs is alarmingly limited. For most platyhelminths including schistosomes, Praziquantel (PZQ) is the commonly used drug. With respect to its regular application in mass treatment programs, however, there is increasing concern about resistance development.Previous studies demonstrated that inhibitors used to treat non-parasitic human diseases may be useful to be tested for their effects on parasites. To this end, we focused on biarylalkyl carboxylic acids (BACAs) as basis, which had been shown before to be interesting candidates in the context of finding alternative approaches to treat diabetes mellitus. We tested 32 chemically modified derivatives of these substances (biarylalkyl carboxylic acid derivatives (BACADs)) for their effects on adult Schistosoma mansoni in vitro. Treatment with 18 BACADs resulted in egg production-associated phenotypes and reduced pairing stability. In addition, 12 of these derivatives affected vitality and/or caused severe tegument damage, gut dilatation, or other forms of tissue disintegration which led to the death of worms. In most cases (10/12), one derivative caused more than one phenotype at a time. In vitro experiments in the presence of serum albumin (SA) and alpha-acidic glycoprotein (AGP) indicated a varying influence of these blood components on the effects of two selected derivatives. The variety of observed phenotypes suggested that different targets were hit. The results demonstrated that BACADs are interesting substances with respect to their anti-schistosomal effects.
血吸虫和其他寄生扁形虫引发了对人类和动物具有全球重要意义的传染病。尽管它们在医学和经济方面具有重要性,但目前尚无可用的疫苗,且药物数量极为有限。对于包括血吸虫在内的大多数扁形虫而言,吡喹酮(PZQ)是常用药物。然而,鉴于其在大规模治疗项目中的常规应用,人们对耐药性的发展日益担忧。先前的研究表明,用于治疗非寄生性人类疾病的抑制剂可能值得测试其对寄生虫的作用。为此,我们聚焦于联芳基烷基羧酸(BACAs)作为基础,此前已表明它们在寻找治疗糖尿病的替代方法方面是有趣的候选物。我们测试了这些物质的32种化学修饰衍生物(联芳基烷基羧酸衍生物(BACADs))对曼氏血吸虫成虫的体外作用。用18种BACADs处理导致了与产卵相关的表型并降低了配对稳定性。此外,其中12种衍生物影响了活力和/或导致严重的体表损伤、肠道扩张或其他形式的组织解体,进而导致虫体死亡。在大多数情况下(10/12),一种衍生物同时会导致不止一种表型。在血清白蛋白(SA)和α-酸性糖蛋白(AGP)存在下的体外实验表明,这些血液成分对两种选定衍生物的作用有不同影响。观察到的表型多样性表明作用的靶点不同。结果表明,BACADs因其抗血吸虫作用而成为有趣的物质。